Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040822 (tremor)
 18,428 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The intensity of the head-twitch response and the 5-hydroxytryptamine (5-HT) syndrome (tremor, fore-paw treading, head-weaving and hind-limb abduction) was measured in male CFLP mice following IP injection of 5 mg/kg 5-methoxy-N,N-dimethyltryptamine (5-MeODMT). The results of separate experiments carried out at 1.5-h intervals throughout the light-dark cycle showed a clear circadian variation in head-twitch, with highest scores mid-light. No circadian variation in the 5-HT syndrome, or in any individual element of it, was observed. Dose-response curves constructed for 5-MeODMT mid-light and mid-dark over the range 2-64 mg/kg IP confirmed the difference in head-twitch response, showing a parallel shift to the right for mid-dark compared to mid-light up to 32 mg/kg. Again, no difference was seen between the two curves for the 5-HT syndrome. Measurement of the time course of behavioural activity following 5-MeODMT failed to show any differences between mid-light and mid-dark, making it unlikely that pharmacokinetic differences account for the observed circadian variation. It is suggested that the demonstration of a circadian rhythm in the head-twitch response and the failure to show any comparable rhythm in the 5-HT syndrome provides further evidence that these behaviours are mediated by different 5-HT receptor subtypes.
 ...
PMID:Circadian variation in behavioural responses to central 5-HT receptor stimulation in the mouse. 392 60

Responses to drugs affecting 5-hydroxytryptamine (5-HT) and dopaminergic (DA) system have been examined in rats after repeated immobilization. Groups of rats were immobilized for 2 h per day for up to 7 days. Twenty-four hours later their behavioural responses to various drugs were tested. Rats immobilized for 7 days showed decreased sniffing and increased grooming and body shakes. When given amphetamine (3 mg/kg, i.p.) the intensity of classical dopamine-dependent behaviours was similar to that of non-immobilized controls. Some responses to the 5-HT releaser p-chloroamphetamine (PCA) (4 and 10 mg/kg, i.p.) and the 5-HT agonist 5-methoxy-N,N-dimethyltryptamine (5-MEODMT) (5 mg/kg, i.p.) (forepaw treading and tremor) were enhanced after 7 days immobilization but others (limb abduction and headweaving) were not. These responses were not enhanced after 1 or 3 days immobilization. Backward walking and body shakes induced by PCA were also enhanced after 7 days immobilization. Concentrations of 5-HT, DA and their metabolites in striatum, cortex, hippocampus, hypothalamus and midbrain of non-drug-treated control and immobilized groups were comparable. Brain PCA concentrations 30 min after injection were also comparable. The above biochemical and behavioural data suggest that repeated immobilization increases some 5-HT postsynaptic functions. These results are discussed in relation to non-drug-provoked behavioural abnormalities occurring 24 h after the first immobilization but no longer evident after 7 periods of immobilization.
 ...
PMID:Enhancement of some 5-HT-dependent behavioural responses following repeated immobilization in rats. 403 15

The effect of chronic corticosterone treatment (50 mg/kg s.c. 2 x daily) for up to 4 days on behavioural responses to drugs affecting 5-hydroxytryptamine (5-HT) and dopamine (DA) systems was examined in rats 20 h after the last treatment, when placed in experimental cages, to which they had become habituated. Corticosterone- and vehicle-treated rats exhibited both comparable spontaneous behavior when given 0.9% NaCl i.p. and showed similar behavioural responses following amphetamine (3 mg/kg i.p.). However, responses to the 5-HT-releasing drug p-chloroamphetamine (PCA, 4 mg/kg i.p.) were altered with decreased head-weaving hind-limb abduction and forepaw treading. Postsynaptic changes appear to be involved as responses to the 5-HT agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 5 mg/kg i.p.) (tremor, hind-limb abduction and forepaw treading) were also decreased. Hind brain and striatal concentration of 5-HT, DA and their metabolites were comparable in corticosterone and vehicle treated rats killed 20 h after the last treatment. Brain PCA levels determined 30 min after injection were also comparable in both groups. PCA induced behaviour was not altered 20 h after 1 day corticosterone treatment or 4 day after 1 day treatment and 5-MeODMT-induced behaviour was not altered 20 h after 14 days treatment with a lower dose of corticosterone (10 mg/kg s.c. x 2). Twenty h after 1 day corticosterone treatment (50 mg/kg s.c. x 2), rats placed in an open field for the first time showed significantly more activity and dropped fewer faecal pellets than controls.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Reduced-5-hydroxytryptamine-dependent behavior in rats following chronic corticosterone treatment. 406 95

The administration of p-chlorophenylalanine to mice prevents the rise in brain 5-hydroxytryptamine concentration associated with ethanol withdrawal but does not affect the increase in brain catecholamines which occurs at the same time. The locomotor excitement, piloerection, tremor and handling convulsions which occur during ethanol withdrawal were not affected. These results suggest that the increase in brain 5-hydroxytryptamine which occurs in ethanol withdrawal is a consequence of increased 5-hydroxytryptamine synthesis and that it is probably not involved in the above behavioural changes of ethanol withdrawal.
 ...
PMID:Effect of p-chlorophenylalanine on brain monoamines and behaviour during ethanol withdrawal in mice. 428 35

1. The actions of rimiterol [erythro(3,4-dihydroxyphenyl, 2-piperidyl methanol hydrobromide)], a new sympathomimetic bronchodilator, have been compared with those of salbutamol and laevoisoprenaline on the heart and lungs, and on contractions of the soleus muscle of cats under chloralose anaesthesia.2. Rimiterol and salbutamol injected intravenously were about equipotent in all tests, and were about 8 times less potent than laevoisoprenaline both in opposing the bronchoconstrictor action of 5-hydroxytryptamine, and in decreasing the tension and degree of fusion of incomplete tetanic contractions of the cat soleus muscle. They were about 19 times less potent than laevoisoprenaline in increasing heart rate.3. The effect on the soleus muscle is considered to be analogous to the muscle tremor that often occurs in man, and the results therefore suggest that systemic administration of bronchodilator doses of rimiterol, like salbutamol, may produce muscle tremor as an unwanted side-effect.4. When equipotent doses to oppose 5-hydroxytryptamine-induced bronchospasm were compared, rimiterol and salbutamol produced less tachycardia than did laevoisoprenaline. In order to match the tachycardia produced by laevoisoprenaline, the doses of rimiterol or salbutamol had to be increased about two and a half times. This safety margin for salbutamol in the cat is considerably less than that reported by others for different species, which suggests that beta(1)- and beta(2)-adrenoceptors may be less clearly differentiated in the cat than they are in other laboratory animals.
 ...
PMID:Actions of the sympathomimetic bronchodilator, rimiterol (R798), on the cardiovascular, respiratory and skeletal muscle systems of the anaesthetized cat. 508 31

1. The drug HA-966 (1-hydroxy-3-amino-pyrrolidone-2), which chemically resembles the cyclic form of GABA, has been studied for neuro-pharmacological properties and for effects on the catecholamine content of the corpus striatum.2. The acute effects on spontaneous behaviour of rodents included flaccid catalepsy and reversible tranquillization in doses which were 5% or less of the lethal dose. Long lasting depression of the CNS, followed by complete recovery, was produced in the cat and the dog. In the monkey HA-966 caused periodical sleeping episodes.3. The exploratory behaviour and the amphetamine-induced motor activity in mice were blocked by HA-966. The toxicity of amphetamine in aggregated mice was only moderately reduced, suggesting that HA-966 differs from neuroleptics.4. Tremors induced by chemical agents (nicotine, zinc and tremorine) were markedly inhibited by HA-966. The muscarinic effects of tremorine were not reduced by HA-966, indicating a selective central antitremor effect.5. HA-966 elevated the threshold to strychnine convulsions and abolished the ipsilateral flexor reflex, while not having motor endplate blocking properties. It is suggested that HA-966 depresses central internuncial neurones.6. In rats and rabbits HA-966 produced synchronous EEG and inhibited the sensory arousal in doses not causing sedation. In the monkey the drug caused a periodical dissociation between ;sleep-EEG' and behaviour.7. In rat brain, HA-966 selectively elevated the dopamine content in the corpus striatum, while no changes in noradrenaline and 5-hydroxytryptamine contents could be demonstrated. The effect was still present when dopa synthesis was inhibited with alpha-methyl-p-tyrosine.8. Several effects of intravenously administered HA-966 became manifest after an appreciable delay and in hepatectomized mice the effects were much reduced. It is postulated that HA-966 is converted to a pharmacologically active metabolite.9. The results are discussed in the light of current views on drug therapy in extrapyramidal conditions and a GABA-related hypothesis as to the mode of action of HA-966 is presented.
 ...
PMID:1-Hydroxy-3-amino-pyrrolidone-2(HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases. 515 20

1. In unanaesthetized rabbits 5-hydroxytryptophan (5-HTP) and 5-hydroxytryptamine (5-HT) were injected into the cisterna magna or into the cannulated left lateral cerebral ventricle while rectal temperature was recorded.2. 5-HTP injected intracisternally in a dose of 1.5-3 mg produced a fall in temperature often followed by a rise beyond the pre-injection level. With 6 mg the main effect was a rise in temperature. The intraventricular injection of 1-2 mg 5-HTP usually produced a fall followed by a rise.3. 5-HT injected intracisternally in a dose of 0.2 mg produced a fall in temperature similar to that produced with this dose injected intraventricularly. Following an intracisternal injection of 1-4 mg 5-HT there was either a fall, or a fall followed by a rise, but in a few experiments the effect consisted mainly of a rise in temperature.4. Additional effects regularly observed with these injections were tachypnoea, ear twitching, rapid movements of the vibrissae, shaking of the head, wiping and scratching movements, ataxia, nodding and sideways movements of the head and long-lasting catalepsy.5. The sites where 5-HTP and 5-HT act when producing the temperature responses and the various behavioural effects are discussed.
 ...
PMID:Temperature responses and other effects of 5-hydroxytryptophan and 5-hydroxytryptamine when acting from the liquor space in unanaesthetized rabbits. 530 31

1. In rats the effect of drugs on oxotremorine tremor and oxotremorine-induced increase in brain acetylcholine has been investigated.2. Reserpine, (+/-)-alpha-methylmetatyrosine and diethyldithio-carbamic acid, drugs which have in common the ability to decrease tissue noradrenaline concentration, inhibited oxotremorine tremor without preventing the oxotremorine-induced increase in brain acetylcholine.3. (+/-)-p-chlorophenylalanine, a depletor of tissue 5-hydroxytryptamine, did not inhibit oxotremorine tremor.4. Phenoxybenzamine and propranolol inhibited oxotremorine tremor, and propranolol was without effect on oxotremorine-induced increase in brain acetylcholine.5. The toxicity of oxotremorine was increased by reserpine and phenoxybenzamine.6. The significance of these findings is discussed with regard to the mode of action of oxotremorine.
 ...
PMID:Effects of drugs on tremor and increase in brain acetylcholine produced by oxotremorine in the rat. 541 85

1 The behavioural responses of drugs known to act through central 5-hydroxytryptamine (5-HT) mechanisms have been investigated in rats receiving a neuroleptic (trifluoperazine) in their drinking water for 4 to 6 months.2 5-Hydroxytryptophan (5-HTP) induced 5-HT-dependent behaviours including head bobbing and lateral head weaving, reciprocal forepaw treading, tremor, backward walking, body writhing and ;wet-dog' shakes. In doses of 50 to 150 mg/kg, 5-HTP induced more intense behavioural effects in neuroleptic-treated rats than in the control animals.3 Similarly the putative 5-HT agonist, quipazine (1 to 20 mg/kg) and the 5-HT releasing drug, fenfluramine (5 to 20 mg/kg), both induced significantly greater motor responses in the chronically neuroleptic-treated rats.4 A 5-HT uptake inhibitor (femoxetine, 2.5 to 10 mg/kg) had little behavioural effect in either control or trifluoperazine-treated rats.5 Total specific high-affinity binding of radiolabelled 5-HT was significantly increased in crude membrane fractions prepared from the cortex, striatum and substantia nigra of neuroleptic-treated rats compared to control animals.6 High-affinity uptake of radiolabelled 5-HT into striatal slices was similar in experimental and control animals.7 Behavioural and biochemical data would indicate that postsynaptic 5-HT mechanisms are enhanced in rats treated chronically with trifluoperazine. Chronic neuroleptic therapy may thereby induce cerebral 5-HT receptor supersensitivity in addition to the well-documented cerebral dopamine receptor supersensitivity.
 ...
PMID:Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment. 611 11

The effects of clomipramine HCl (15 mg kg-1 i.p.) on behaviour, body temperature and brain amines were investigated in rats that had been chronically treated twice daily with increasing doses of delta 9-tetrahydrocannabinol (delta 9-THC, 2-6 mg kg-1 i.v.). delta 9-THC produced a biphasic change in behaviour, stimulation followed by depression, and a pronounced hypothermia. Tolerance developed rapidly to these effects of delta 9-THC. Chronic treatment with delta 9-THC reduced the levels of homovanillic acid, 5-hydroxytryptamine and noradrenaline. The level of dopamine was not altered with chronic treatment and tolerance appeared to develop to the increased levels of 5-hydroxyindoleacetic acid induced by delta 9-THC. Injection of clomipramine, 12-14 h after 2, 5 or 10 days of delta 9-THC treatment induced characteristic changes in the rats behaviour which consisted of writhes, backward kicking, wet shakes, jumps ataxia and front paw and whole body tremor. The severity of the behavioural changes appeared to be dependent on the period of delta 9-THC administration and they were not accompanied by a change in body temperature or consistent changes in brain amines or metabolites. The results indicate that physical dependence on delta 9-THC may occur since clomipramine is able to precipitate changes in behaviour, indicative on an abstinence syndrome, in rats chronically treated with delta 9-THC. It is suggested that tryptaminergic mechanisms are altered during chronic delta 9-THC treatment and that clomipramine induces the behavioural changes by interacting with an altered tryptaminergic system.
 ...
PMID:Time-course of the effects of chronic delta 9-tetrahydrocannabinol on behaviour, body temperature, brain amines and withdrawal-like behaviour in the rat. 612 98


<< Previous 1 2 3 4 5 6 7 Next >>